Neuroepidemiology · Nov 9, 2026
Systematic Review of Population-Based Studies of Prevalence and Incidence of Aging-Associated Neurodegenerative Diseases in Russia
By Okhotin A, Gorbunova I, Bolshakov A
AIM: To systematically review population-based studies reporting the prevalence or incidence of dementia, cognitive dysfunction, and Parkinson's disease among adults aged 50 years and older in Russia. SUBJECTS AND METHODS: We searched MEDLINE, Scopus, Embase, and eLibrary from inception to January 2025, supplemented by grey-literature searches and citation checking. Cross-sectional and cohort studies reporting population-based prevalence or incidence estimates were eligible. Convenience samples from healthcare institutions and institutionalised populations without a population denominator were excluded, whereas population-based administrative records were eligible. Risk of bias was assessed using the RoB-PrevMH tool. For studies using MMSE or Mini-Cog, projected dementia prevalence was calculated by adjusting screen-positive proportions for test sensitivity and specificity. Prevalence estimates were synthesised by inverse-variance meta-analysis on the logit scale, stratified by age group and ascertainment method. Random-effects estimates were considered primary; incidence estimates were not pooled. RESULTS: Twenty papers describing 17 distinct study populations met the inclusion criteria: 11 papers reported cognitive outcomes and 9 reported Parkinson's disease. Direct expert-diagnosis estimates of dementia prevalence were available from two older studies and ranged from 6.7% to 10.5% in adults older than 60 years. Registered prevalence based on administrative data was substantially lower, at approximately 0.5-0.6%. Screen-positive proportions based on MMSE or Mini-Cog ranged from 3.1% to 81.5%. After adjustment for test sensitivity and specificity, projected dementia prevalence reached 81.6% in a single Mini-Cog stratum aged 75-84 years; the random-effects pooled estimate for the nominal 75-84-year group was 54.1% (95% CI 18-87). Two screening strata were incompatible with the assumed test-accuracy parameters. Administrative estimates of Parkinson's disease prevalence ranged from 0.017% to 0.29%; the only neurologist-assessed population study reported 0.31%. CONCLUSION: Estimates varied markedly according to age, study design, and ascertainment method. Administrative data probably underestimate disease prevalence, whereas estimates derived from single cognitive screening tests are sensitive to assumptions about diagnostic accuracy. Available studies are regionally restricted and methodologically heterogeneous and do not provide reliable national prevalence or incidence estimates. Population-based longitudinal studies using validated diagnostic methods are needed to support health policy in Russia.